CBAY

Cymabay Therapeutics
CBAY

Overview Fund Activity
Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

118 hedge funds and large institutions have $396M invested in Cymabay Therapeutics in 2022 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 30 increasing their positions, 29 reducing their positions, and 7 closing their positions.

Holders
118
Holders Change
+18
Holders Change %
+18%
% of All Funds
1.9%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
26
Increased
30
Reduced
29
Closed
7
Calls
$2.79M
Puts
$1.5M
Net Calls
+$1.29M
Net Calls Change
+$947K

Top Buyers

1
OCA
1
Octagon Capital Advisors
New York
$11.7M
2
LGM
2
Logos Global Management
California
$7.84M
3
Janus Henderson Group
3
Janus Henderson Group
United Kingdom
$7.79M
4
ACP
4
Acuta Capital Partners
California
$6.36M
5
GPP
5
Great Point Partners
Connecticut
$9.72M

Top Sellers

1
DCM
1
DAFNA Capital Management
California
$1.07M
2
ACM
2
Altium Capital Management
New York
$6.43M
3
LCM
3
Lynx1 Capital Management
Puerto Rico
$10.4M
4
Hudson Bay Capital Management
4
Hudson Bay Capital Management
Connecticut
$4.37M
5
Millennium Management
5
Millennium Management
New York
$5.83M
Name Market Value Shares Shares
Change 		Shares
Change %
Simplex Trading
126
Simplex Trading
Illinois
– – – –
CFGS
127
Concourse Financial Group Securities
Alabama
– – – –
CM
128
Caption Management
Oklahoma
– – – –
2 3 4 5
6